Citations

Clear

3030 citation(s) found for "Susan, M".

A phase 1 study of the c‐Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111)
Perentesis, John P. , Liu, Xiaowei , Kudgus, Rachel A. , Fox, Elizabeth , Blaney, Susan M. , Weigel, Brenda J. , Reid, Joel M. , Geller, James I. , Minard, Charles G.

Mayo Clinic

Pediatric Blood & Cancer | April 27, 2017 | Volume: 64 | Issue: 11 | Pages: No page available

10.1002/pbc.26565 | PMID 28449393 Get It

AbstractBackgroundThe c‐Met receptor tyrosine kinase is dysregulated in many pediatric cancers. Tivantinib is an oral small molecule that inhibits the c‐Met receptor tyrosine kinase. A phase 1 and pharmacokinetic (PK) trial evaluating tivantinib was conducted in children with relapsed/refractory solid tumors.MethodsOral tivantinib capsules were administered twice daily with food, continuously in 28‐day cycles. Dose levels 170, 200, and 240 mg/m2/dose were evaluated using a rolling‐six design (Part A). In Part B, subjects received tivantinib powder sprinkled on food at the recommended phase 2 dose (RP2D) from Part A. PK, CYP2C19 genotyping, and baseline tumor tissue c‐Met expression were analyzed.ResultsThirty‐six patients were enrolled: 20 in Part A, 6 in a PK expansion cohort, and 10 in Part B. Fifteen patients had primary central nervous system tumors and 21 had solid tumors. In Part A, there were no dose‐limiting toxicities. One grade 4 intracranial hemorrhage occurred in a patient with a progressive brain tumor in the expanded PK cohort (240 mg/m2). PK analysis showed marked interpatient variability (20‐fold) in the Cmax and AUC0‐8h across all dose levels. Sprinkling tivantinib powder over food did not alter exposure. Membranous and total c‐Met expression was moderate (2), low (4), or not detected (26). Two patients had stable disease as the best response.ConclusionsThe RP2D of tivantinib given with food in children with refractory solid tumors is 240 mg/m2/dose. PK of tivantinib in children demonstrated high variability. Objective responses were not observed in this phase 1 trial.
Supplement Use and Chemotherapy-Induced Peripheral Neuropathy in a Cooperative Group Trial (S0221): The DELCaP Study
Zirpoli, Gary , McCann, Susan E. , Sucheston‐Campbell, Lara E. , Ciupak, Gregory, Davis, Warren , Stewart, James A. , Hobday, Timothy J. , Salim, Muhammad , Budd, G. Thomas , Albain, Kathy S. , Hershman, Dawn L. , Unger, Joseph M. , Moore, Halle C. F. , Isaacs, Claudine , Hortobágyi, Gabriel N. , Gralow, Julie R. , Ambrosone, Christine B. , Zirpoli, Gary

Mayo Clinic

JNCI: Journal of the National Cancer Institute | April 25, 2017 | Volume: 109 | Issue: 12 | Pages: No page available

10.1093/jnci/djx098 | PMID 29546345 Get It

Helicobacter Pylori Infection in Texas Hispanic and Non-Hispanic White Men: Implications for Gastric Cancer Risk Disparities
Parma, Dorothy Long , Muñoz, Edgar , Ogden, Susan M., Westin, Gustavo Figueiredo Marcondes, Leach, Robin J. , Thompson, Ian M. , Westin, Gustavo F, Ramirez, Amelie G , Thompson, Ian M

Mayo Clinic

American Journal of Men's Health | April 17, 2017 | Volume: 11 | Issue: 4 | Pages: 1039-1045

10.1177/1557988317702038 | PMID 28413904 Get It

Chronic Helicobacter pylori ( H. pylori) infection is a major gastric adenocarcinoma (GA) risk factor. GA disproportionately affects U.S. Hispanics compared with non-Hispanic Whites (NHWs). Since H. pylori infection studies in Hispanics are few, infection rates in Hispanic and NHW men in Bexar County were compared, and relationships with ethnicity and obesity examined. Age- and zip code-matched participants from a community-dwelling cohort were randomly selected. Sera from 284 men were analyzed by enzyme immunoassay for H. pylori antibodies. Adjusted risk ratio estimation for matched data was conducted to identify differences. Hispanics had a markedly higher prevalence of infection (30.3%) than NHWs (9.2%). Matched risk ratio (mRR) analyses revealed a strong association between H. pylori seropositivity and Hispanic ethnicity (mRR = 3.31; 95% CI [1.91, 5.73], adjusted by BMI, smoking status, and family history of cancer (mRR range = 3.28-3.89). BMI mRRs (range = 1.19-1.22) were significant in all models. In this cohort, Hispanic men had higher H. pylori infection rates than NHWs, and parallel the disproportionately higher rates of GA; obesity contributes to this higher prevalence. Future studies should address country of origin, acculturation, and other factors influencing obesity to further elucidate risk of GA in Hispanic populations.
External Arrhythmia Ablation Using Photon Beams
Deisher, A., Takami, Mitsuru , Kruse, Jon J. , Song, Limin, Anderson, Sarah , Cusma, Jack T., Parker, Kay D., Johnson, Susan B., Asirvatham, Samuel J. , Miller, Robert C. , Herman, Michael , Packer, Douglas L. , Lehmann, H. Immo , Deisher, Amanda J, Anderson, Sarah E, Herman, Michael G., Asirvatham, Samuel J

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | April 13, 2017 | Volume: 10 | Issue: 4 | Pages: No page available

10.1161/circep.116.004304 | PMID 28408649 Get It

Background— This study sought to investigate external photon beam radiation for catheter-free ablation of the atrioventricular junction in intact pigs. Methods and Results— Ten pigs were randomized to either sham irradiation or irradiation of the atrioventricular junction (55, 50, 40, and 25 Gy). Animals underwent baseline electrophysiological evaluation, cardiac gated multi-row computed tomographic imaging for beam delivery planning, and intensity-modulated radiation therapy. Doses to the coronary arteries were optimized. Invasive follow-up was conducted ≤4 months after the irradiation. A mean volume of 2.5±0.5 mL was irradiated with target dose. The mean follow-up length after irradiation was 124.8±30.8 days. Out of 7 irradiated animals, complete atrioventricular block was achieved in 6 animals of all 4 dose groups (86%). Using the same targeting margins, ablation lesion size notably increased with the delivered dose because of volumetric effects of isodose lines around the target volume. The mean macroscopically calculated atrial lesion volume for all 4 dose groups was 3.8±1.1 mL, lesions extended anteriorly into the interventricular septum. No short-term side effects were observed. No damage was observed in the tissues of the esophagus, phrenic nerves, or trachea. However, histology revealed in-field beam effects outside of the target volume. Conclusions— Single-fraction doses as low as 25 Gy caused a lesion with interruption of cardiac impulse propagation using this respective target volume. With doses of ≤55 Gy, maximal point-doses to coronary arteries could be kept <7Gy, but target conformity of lesions was not fully achieved using this approach.
CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia
Chaffee, Kari G. , Achenbach, Sara J., Call, Timothy G. , Jelinek, Diane F., Hanson, Curtis A. , Rabe, Kari G. , Strati, Paolo , Strati, Paolo , Parikh, Sameer A. , Slager, Susan L. , Ding, Wei , Kay, Neil E. , Shanafelt, Tait D.

Mayo Clinic

British Journal of Haematology | April 7, 2017 | Volume: 178 | Issue: 1 | Pages: 99-105

10.1111/bjh.14647 | PMID 28386906 Get It

SummaryCD49d is a surface integrin that is expressed on chronic lymphocytic leukaemia (CLL) cells, and strongly correlates with more aggressive disease. Given its association with cell‐cell adhesion and leucocyte trafficking, we hypothesized that patients with high CD49d expression would experience a clinical course dominated by lymphadenopathy. CD49d expression was measured by flow cytometry and considered positive if expressed by ≥30% of CLL cells. The study included 797 newly diagnosed CLL/small lymphocytic leukaemia patients; 279 (35%) were CD49d positive. CD49d‐positive patients were more likely to present with lymphadenopathy (P < 0·001); a finding that persisted after adjusting for fluorescence in situ hybridisation (FISH) and IGHV mutation status [odds ratio (OR) 2·51; 95% confidence interval (CI) 1·64–3·83; P < 0·001]. Among CLL Rai 0 patients, CD49d positivity was associated with shorter time to development of lymphadenopathy (3·2 years vs not reached, P < 0·01). This association was maintained after adjusting for either FISH [hazard ratio (HR) 2·18; 95% CI 1·25–3·81; P = 0·006) or IGHV status (HR 2·02; 95% CI 1·11–3·69; P = 0·02) individually, but was attenuated when adjusting by both (HR 1·72; 95% CI 0·88–3·38; P = 0·11).These data demonstrate that CD49d‐positive CLL patients experience a disease course dominated by lymphadenopathy. These findings could have implications for therapy selection and disease monitoring.
A phase 3 trial of IV immunoglobulin for Alzheimer disease
Relkin, Norman R., Thomas, Ronald G., Rissman, Robert A., Brewer, James B., Rafii, Michael S., Dyck, Christopher H. van, Jack, Clifford R., Sano, Mary, Knopman, David S., Raman, Rema, Szabo, Paul, Gelmont, David M., Fritsch, Sandor, Aisen, Paul S., Study, For the Alzheimer's Disease Cooperative, Study, Alzheimer's Disease Cooperative, Ahern, Geoffrey, Yaari, Roy, Sabbagh, Marwan, Mirza, Nadeem, Bernick, Charles, Bell, Karen, Turner, R. Scott, Obisesan, Thomas, Chertkow, Howard, Zabar, Yuval, Knopman, David, Mintzer, Jacobo, Grossman, Hillel, Sadowski, Martin, Wu, Chuang-Kuo, Quinn, Joseph, Borrie, Michael, Petrie, William, Ott, Brian, Keegan, Andrew, Grossberg, George, Sabbagh, Marwan, Bari, Moammed, Cohen, Sharon, Richter, Ralph, Lerner, Alan, Mulnard, Ruth, Potkin, Steven, Rafii, Michael, Brockington, John, Hsiung, Robin, Schultz, Susan, Burns, Jeffrey, Jicha, Gregory, Burke, William, Arnold, Steven, Porsteinsson, Anton, Smith, Amanda, Schneider, Lon, Quiceno, Mary, Zamrini, Edward, Asthana, Sanjay, Burgat, FT, Duara, Ranjan, Dyck, Christopher van, Jack, Clifford R. , Hsiung, Ging‐Yuek Robin , Jicha, Gregory A. , Sadowski, Martin , van Dyck, Christopher H, Relkin, Norman R., Thomas, Ronald G., Rissman, Robert A., Brewer, James B., Rafii, Michael S., Dyck, Christopher H. van, Sano, Mary, Knopman, David S., Raman, Rema, Szabo, Paul, Gelmont, David M., Fritsch, Sandor, Aisen, Paul S., Study, For the Alzheimer's Disease Cooperative, Study, Alzheimer's Disease Cooperative, Ahern, Geoffrey, Yaari, Roy, Sabbagh, Marwan, Mirza, Nadeem, Bernick, Charles, Bell, Karen, Turner, R. Scott, Obisesan, Thomas, Chertkow, Howard, Zabar, Yuval, Knopman, David, Mintzer, Jacobo, Grossman, Hillel, Wu, Chuang-Kuo, Quinn, Joseph, Borrie, Michael, Petrie, William, Ott, Brian, Keegan, Andrew, Grossberg, George, Sabbagh, Marwan, Bari, Moammed, Cohen, Sharon, Richter, Ralph, Lerner, Alan, Mulnard, Ruth, Potkin, Steven, Rafii, Michael, Brockington, John, Schultz, Susan, Burns, Jeffrey, Burke, William, Arnold, Steven, Porsteinsson, Anton, Smith, Amanda, Schneider, Lon, Quiceno, Mary, Zamrini, Edward, Asthana, Sanjay, Burgat, FT, Duara, Ranjan, Dyck, Christopher van, Jack, Clifford R , Hsiung, Gink-Yuek , Jicha, Gregory A

Mayo Clinic

Neurology | April 6, 2017 | Volume: 88 | Issue: 18 | Pages: 1768-1775

10.1212/wnl.0000000000003904 | PMID 28381506 Get It

Multicentre study of posaconazole delayed-release tablet serum level and association with hepatotoxicity and QTc prolongation
Rivera, Christina G. , Narayanan, Prasanna P., Perissinotti, Anthony J. , Gedrimaite, Zivile, Han, Zhe , Steinbeck, Jennifer L, Pisano, Jennifer , Seo, Susan K. , Paskovaty, Alla , Pettit, Natasha N. , Miceli, Marisa H. , Hsu, Meier , Delacruz, Jennifer, Rivera, Christina G

Mayo Clinic

Journal of Antimicrobial Chemotherapy | April 5, 2017 | Volume: 72 | Issue: 8 | Pages: 2355-2358

10.1093/jac/dkx122 | PMID 28475803 Get It

Phase 2 study of PS-341 (bortezomib) in the treatment of metastatic malignant melanoma (MMM)
Geyer, Susan M. , Markovic, Svetomir, Fitch, Tom R., Albertini, Mark R. , Maples, William J., Fracasso, Paula M. , Erlichman, Charles , Markovic, Svetomir N.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 7526-7526

10.1200/jco.2004.22.90140.7526 Get It

NCCTG trial of concomitant or sequential IL-12 in combination with rituximab in previously treated non-Hodgkin lymphoma patients
Ansell, Stephen M. , Geyer, Susan M. , Jelinek, Diane F., Kurtin, Paul J. , Micallef, Ivana N. , Stella, Philip J., Etzell, Paul S., Erlichman, Charles , Novak, Anne J. , Witzig, Thomas E.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 6591-6591

10.1200/jco.2004.22.90140.6591 Get It

Initial results of a pilot study of epratuzumab and rituximab in combination with CHOP chemotherapy (ER-CHOP) in previously untreated patients with diffuse large B-cell lymphoma (DLBCL)
Micallef, Ivana N. , Gayko, Urte, Cesano, Alessandra, Ansell, Stephen M. , Geyer, Susan M. , Inwards, David J. , Horning, Sandra J., Kahl, Brad S. , Maurer, Matthew J. , Habermann, Thomas M.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 6580-6580

10.1200/jco.2004.22.90140.6580 Get It